Key Highlights
- 2.3% is the gap between Eli Lilly (NYSE:LLY) at USD 1,262.45 and its USD 1,292.65 high, the narrowest of four large caps, per published market data on October 16, 2026 intraday. Microsoft is furthest, 3.0% below an implied USD 553.6 high.
- 35.1 times is the forward multiple of Eli Lilly (NYSE:LLY) on the USD 36.00 EPS guidance midpoint, against 19.0 times for Amgen and 20.5 times for AbbVie, own arithmetic. Microsoft is quoted on a trailing P/E of 28, so it is excluded from that comparison.
- 70.5 is the RSI of AbbVie (NYSE:ABBV), the only reading above the 70 overbought line, against 69.4 for Lilly, 64.9 for Amgen and 63.0 for Microsoft, per published market data on October 16, 2026. RSI describes momentum, not value.
- October 28, 2026 is the fiscal first quarter report date of Microsoft (NASDAQ:MSFT), followed by Eli Lilly on October 29 and AbbVie on October 30. The Amgen third quarter date was not confirmed in the materials reviewed; the second quarter was reported August 4, 2026.
Eli Lilly (NYSE:LLY)
Eli Lilly is the closest to its high and the most expensive. It rose 3.55% to a USD 1,251.61 close on October 15, 2026 with no company announcement identified, then added 0.87% to USD 1,262.45 on October 16. Second quarter revenue of USD 23.0 billion rose 48% as volume grew 60% and realized prices fell 13%, per the August 5, 2026 company release. Guidance was raised to USD 85.0 billion to USD 87.0 billion of revenue and USD 35.50 to USD 36.50 of EPS. The stock sits 61.1% above its USD 783.85 low (own arithmetic). Morgan Stanley holds a USD 1,430 target and Cantor Fitzgerald USD 1,440, both above the price. The specific risk is price erosion: prices outside the United States fell 36% after China reimbursement, so volume must keep outrunning cuts, and non-GAAP EPS of USD 8.38 absorbed USD 3.03 of acquired development charges. Eli Lilly (NYSE:LLY) reports on October 29, 2026, with an RSI of 69.4 below the overbought line.
Microsoft (NASDAQ:MSFT)
Microsoft is the largest company here, with a USD 3.99 trillion market value, and the only one with a disputed high. At USD 536.96 on October 16, 2026, a 3.0% distance implies a USD 553.6 high, while USD 549.20 was published on October 2; against that figure the gap is 2.2% (own arithmetic). Fiscal fourth quarter revenue of USD 90.01 billion beat the USD 87.63 billion estimate, and Azure grew 43%, per the July 29, 2026 report. Commercial backlog of USD 678 billion, up 84%, is reported and not independently confirmed, and growth excluding OpenAI was 25%. Operating cash flow rose 30% to USD 55.44 billion, but free cash flow fell 23.19% as capital spending rose 109.63%, and fiscal 2027 spending is guided to approximately USD 175 billion. Microsoft (NASDAQ:MSFT) carries a trailing P/E of 28 and an RSI of 63.0. The October 28, 2026 call tests Azure guidance of approximately 45%.
AbbVie (NYSE:ABBV)
AbbVie is the only name with an RSI above 70. Shares rose 0.29% to USD 284.21 on October 16, 2026, 2.5% below the USD 291.40 high, on a USD 502.23 billion market value. The October 5, 2026 8-K disclosed USD 216 million of acquired IPR&D and milestones expense, a USD 0.11 per share third quarter effect, which cut full-year adjusted EPS guidance to USD 13.76 to USD 13.96. Such expense is booked at once, so it is an accounting charge, not weaker demand. Second quarter Skyrizi and Rinvoq revenue of USD 8.030 billion was 47.3% of USD 16.990 billion net revenues (own arithmetic), while Humira fell 35.9%. AbbVie (NYSE:ABBV) trades at 20.5 times the USD 13.86 guidance midpoint (own arithmetic). Morgan Stanley's target is USD 310, Bank of America's USD 305 and UBS's USD 275, which is below the price. Tariff exposure is not disclosed in the material reviewed, so the sector tariff framework is an unquantified risk for investors. Results are due October 30, 2026 before the open.
Amgen (NASDAQ:AMGN)
Amgen is 2.4% below its USD 447.03 high at USD 436.09, yet has the weakest analyst support. The average target of USD 387.93 is 11.0% below the price, and the consensus across 30 analysts is Hold. Second quarter revenue rose 9.5% to USD 10.054 billion on volume, with Repatha up 37% and Evenity up 38%, per the company release. Guidance of USD 22.30 to USD 23.50 of non-GAAP EPS puts Amgen (NASDAQ:AMGN) at 19.0 times the midpoint, the lowest multiple of the four. The shares sit 51.4% above their USD 288.00 low (own arithmetic). Net debt is USD 43.3 billion (own arithmetic, USD 57.3 billion of debt less USD 14.0 billion of cash), and non-GAAP operating margin slipped 0.5 percentage points to 48.4%. MariTide has no Phase 3 efficacy data yet, so the obesity opportunity is not in reported numbers. Market value was not stated in the materials reviewed, so Amgen is unranked by size.
Where Things Stand
No one of the four is clearly ahead, because proximity to a high and valuation point in different directions. Ranked by distance below the high: Eli Lilly (NYSE:LLY) 2.3%, Amgen 2.4%, AbbVie 2.5% and Microsoft 3.0%, own arithmetic on published figures. Amgen (NASDAQ:AMGN) is cheapest at 19.0 times forward EPS, then AbbVie at 20.5 times and Lilly at 35.1 times; Microsoft is excluded because its 28 times is trailing. AbbVie (NYSE:ABBV) is the only name above an RSI of 70. The earnings run starts October 28, 2026 with Microsoft (NASDAQ:MSFT), then Lilly on October 29 and AbbVie on October 30. Amgen is undated. The distances are one intraday snapshot, and each report can change the order within days.






Please wait processing your request...